Poster B002: Developing Novel Immuno-Oncology Assays for Anti-CD47 Research

CD47 Expression Predicts Efficacy of Macrophage-Mediated Phagocytosis of Tumor Cells

Huajun Yang, Zhongliang Li, Beibei Tang, Wanqiu Zhuang, Danting Yan, Frank Xing, and Qian Shi

Expressing CD47 is a technique used by most human tumors to escape macrophage surveillance. Targeting CD47 to reinstate macrophage functionality in clearing tumor cells is therefore an important and novel strategy in immuno-oncology.

Robust preclinical platforms are needed to enable research into anti-CD47 immunotherapies, including in vitro assay platforms. Therefore, CrownBio has developed a macrophage differentiation system followed by M1/M2 activation.

This in vitro phagocytosis assay co-cultures activated macrophages with target tumor cells and CFSE labeling for flow cytometry, allowing the phagocytic effects of anti-CD47 agents and other related immunotherapeutics to be assessed.

Read this Poster to Discover:

• That CD47 expression level varies in different cancer cell models, and that Karpas299 is a valid alternative to the commonly used SK-OV-3 in phagocytosis studies, expressing more CD47 and inducing more robust target engulfing activity.
  
  
• How strong positive correlations between phagocytic activity and CD47 expression level are observed in isogenic models (Karpas299-hCD47 and SK-OV-3-hCD47 stable cell lines) and their parental cell lines.
  
  
• How disrupting the CD47-SIRPa anti-phagocytic axis is a novel immunotherapy approach against cancer.

Download the Poster Now!